Newron Pharmaceuticals SpA stock analysis
Newron Pharmaceuticals SpA (0QOI) Share Price & Analysis
0QOI Stock Chart & Stats
- Day’s Range
- CHF 8.71 - CHF 8.84
- 52-Week Range
- CHF 6.49 - CHF 31.85
- Previous Close
- CHF 8.85
- Volume
- N/A
- Average Volume (3M)
- 1,161
- Market Cap
- CHF 181.80M
- Enterprise Value
- CHF 273.34M
- Total Cash (Recent Filing)
- CHF 32.99M
- Total Debt (Recent Filing)
- CHF 39.16M
- Price to Earnings (P/E)
- ―
- Beta
- 1.80
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- -0.71
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
CNS Therapeutic Focus
A focused pipeline in serious neurological and psychiatric disorders gives Newron a clear therapeutic mission and the potential to build expertise around complex CNS development. If candidates progress, this specialization can support partnering interest and multiple future development opportunities.
Partnering-Based Revenue Model
The partnering model can provide several sources of economic value from a successful candidate, including upfront consideration, development and commercial milestones, and royalties. This structure may help monetize innovation without requiring Newron to build a large commercial organization itself.
Improved Cash Generation
The sharp improvement in operating and free cash flow provides a meaningful financial positive relative to cash burn in 2021–2024. Sustained conversion would improve funding capacity for clinical work and reduce reliance on external financing, although consistency remains unproven.
Bears Say
Negative Equity And Leverage
Negative equity and substantial debt materially restrict financial flexibility. They increase refinancing and dilution risk, potentially forcing Newron to raise capital or adjust development plans on unfavorable terms, while leaving less balance-sheet capacity to absorb setbacks in clinical or partnering activity.
Sharp Revenue And Earnings Deterioration
The steep revenue decline and return to sizable losses show that recent financial performance is not stable. Weak operating margins can limit internally funded research and increase dependence on milestone receipts, licensing transactions, or external capital to sustain development.
Recurring Losses And Episodic Revenue
Recurring losses across most years indicate that profitability has not yet become a durable feature of the business. Dependence on episodic revenue events makes results difficult to forecast and may produce uneven funding for the clinical pipeline, especially when transactions or milestones are delayed.
Newron Pharmaceuticals SpA News
0QOI FAQ
What was Newron Pharmaceuticals SpA’s price range in the past 12 months?
What is Newron Pharmaceuticals SpA’s market cap?
When is Newron Pharmaceuticals SpA’s upcoming earnings report date?
How were Newron Pharmaceuticals SpA’s earnings last quarter?
Is Newron Pharmaceuticals SpA overvalued?
Does Newron Pharmaceuticals SpA pay dividends?
What is Newron Pharmaceuticals SpA’s EPS estimate?
How many shares outstanding does Newron Pharmaceuticals SpA have?
What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Newron Pharmaceuticals SpA
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stefan Weber
- Employees
- 27
- Website
- www.newron.com
- Address
- Via Antonio Meucci 3, Bresso, MI, 20091, IT
Newron Pharmaceuticals SpA (0QOI) Earnings & Revenues
0QOI Earnings Call
Earnings Call SentimentPositive
The call presented multiple strong positive developments: validation from a top-tier partner (Eisai) and EUR 48m collected, a large global pivotal program across >1,300 patients with significant Phase III/Phase II efficacy signals (8A: PANSS p=0.006; CGI-S p=0.037), an improved IP position (European crystalline patent and potential U.S. grant to extend exclusivity to 2044), robust safety/tolerability and clear commercial expansion potential. Management has secured non-dilutive runway and delayed debt service to mid-2028. Principal risks flagged were operational recruitment challenges, parts of funding conditional on positive results (EUR 12m), pending U.S. patent timing, and the fact that a NASDAQ uplisting is not currently achievable without further progress. On balance the highlights (clinical validation, funding, IP progress, safety, analyst coverage) substantially outweigh the lowlights, though the company remains dependent on upcoming pivotal readouts and execution.
View all GB:0QOI earnings summaries0QOI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |










